From:
`To:
`Cc:
`
`Subject:
`Date:
`
`Trials
`Sadasivan, Bhanu; Trials
`Ambry Esoterix MWE; tmckeon@kilpatricktownsend.com; jalemanni@kilpatricktownsend.com;
`bhsing@bakerlaw.com; Matias Ferrario; cwray@kilpatricktownsend.com; jgrier@bakerlaw.com;
`paul.sun@elliswinters.com; kquicker@bakerlaw.com; Mohr, Judy; Alwine, Amy
`RE: IPR2017-002086; IPR2017-002093; IPR2017-002095; and IPR2017-002096
`Friday, March 23, 2018 9:47:10 AM
`
`Counsel:
` 
`The Board authorizes the parties to file a joint motion to terminate the proceeding(s) pursuant to 35
`U.S.C. § 317(a) and 37 C.F.R. § 42.72.  The joint motion must:  (1) include a brief explanation as to
`why termination is appropriate; (2) identify all parties in any related district court litigation involving
`the patent(s) in dispute and discuss the current status of each such related litigation with respect to
`each party to the litigation, and (3) identify the case numbers of any pending, related inter partes
`review proceedings. 
` 
`The joint motion to terminate must be accompanied by a true copy of the parties’ settlement
`agreement, including any collateral agreements referred to in such agreement, as required by 35
`U.S.C. § 317(b) and 37 C.F.R. § 42.74(b), filed as an exhibit.  A redacted version of the settlement
`agreement will not be accepted as a true copy of the settlement agreement.  Under 37 C.F.R. §
`42.74(c), the parties may file a confidential settlement agreement electronically as an exhibit in
`accordance with the instructions provided on the Board’s website (uploading as “Parties and Board
`Only”).  The parties are directed to FAQ G2 on the Board’s website at
`https://www.uspto.gov/patents-application-process/patent-trial-and-appeal-board/ptab-e2e-
`frequently-asked-questions for instructions on how to file their settlement agreement as
`confidential.
` 
`The joint motion(s) shall be filed no later than the close of business March 30, 2018.
` 
`Thank you,
` 
`Maria Vignone
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`703-756-1288
` 
` 
` 
` 
`From: Sadasivan, Bhanu [mailto:Bsadasivan@mwe.com] 
`Sent: Thursday, March 22, 2018 3:16 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Ambry Esoterix MWE <AmbryEsoterixMWE@mwe.com>; tmckeon@kilpatricktownsend.com;
`jalemanni@kilpatricktownsend.com; bhsing@bakerlaw.com; Matias Ferrario
`<mferrario@kilpatricktownsend.com>; cwray@kilpatricktownsend.com; jgrier@bakerlaw.com;
`paul.sun@elliswinters.com; kquicker@bakerlaw.com; Mohr, Judy <Jmohr@mwe.com>; Alwine, Amy
`
`Ambry Exhibit 1032
`
`

`

`<Aalwine@mwe.com>
`Subject: IPR2017-002086; IPR2017-002093; IPR2017-002095; and IPR2017-002096
` 
`To whom it may concern:
` 
`Petitioner Ambry Genetics Corporation respectfully requests a conference call with the Board to
`request leave to file joint motions with patent owner to terminate IPR2017-02086 and IPR2017-
`02093 instituted proceedings under 35 U.S.C. § 317(a).  The parties have entered into a confidential
`settlement agreement pursuant to which the petitioner and the patent owner agree to terminate
`the two recently-instituted proceedings, not to take any further action, including requests for
`rehearing, on the non-instituted IPRs (IPR2017-2095 and IPR2017-2096),  and the parties have
`agreed to terminate with prejudice the related district court litigation, Esoterix Genetic Laboratories,
`LLC and The Johns Hopkins University v. Ambry Genetics Corporation, 16-cv-1111 (M.D.N.C.). 
`
`Patent owner does not oppose this request for a conference call with the Board or the request to
`terminate the two IPR proceedings.
`
`Counsels for the parties are available for the requested conference call at the Board’s convenience.
`
`Respectfully,
`Bhanu K. Sadasivan
`Lead counsel for Petitioner
` 
`Bhanu K. Sadasivan, Ph.D.
`Partner
`McDermott Will & Emery LLP | 275 Middlefield Road, Suite 100 | Menlo Park, CA 94025
`Tel +1 650 815 7537 | Mobile +1 408 306 8400 | Fax +1 650 815 7401
`
`Biography | Website | vCard | Email | Twitter | LinkedIn | Blog
`
` 
`
`*******************************************************************************************************************
`This message is a PRIVILEGED AND CONFIDENTIAL communication. This message and all
`attachments are a private communication sent by a law firm and may be confidential or protected by
`privilege. If you are not the intended recipient, you are hereby notified that any disclosure, copying,
`distribution or use of the information contained in or attached to this message is strictly prohibited. Please
`notify the sender of the delivery error by replying to this message, and then delete it from your system.
`Thank you.
`*******************************************************************************************************************
`
`Please visit http://www.mwe.com/ for more information about our Firm.
`
`Ambry Exhibit 1032
`
`